The management of heart failure in Sweden-the physician's perspective: a survey

Giulia Ferrannini1,2, Mattia Emanuele Biber1,3, Sam Abdi1,4

  • 1Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Insights

Physicians in Sweden face barriers to guideline-directed medical therapy (GDMT) for heart failure (HF), including side effects and knowledge gaps. Improving education and nurse-led clinics can enhance GDMT adherence.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Healthcare Management

Background:

  • Heart failure (HF) management relies on guideline-directed medical therapy (GDMT).
  • Understanding physician-reported barriers is crucial for optimizing HF care in Sweden.

Purpose of the Study:

  • To assess barriers to GDMT use in heart failure (HF).
  • To evaluate diagnostic workup and physician knowledge regarding HF in Sweden.

Main Methods:

  • A survey on HF management was distributed to 828 Swedish physicians (GPs and specialists).
  • Data were collected on diagnostic practices, GDMT implementation barriers, and HF knowledge.
  • Comparisons were made between general practitioners (GPs) and specialists.

Main Results:

  • Major obstacles to GDMT implementation in HF with reduced ejection fraction included side effects and lack of specialist knowledge.
  • Specialists demonstrated higher correct response rates on HF knowledge questions compared to GPs.
  • Most physicians (86%) believe GDMT should be implemented maximally, and 57% see value in nurse-led HF clinics for adherence.

Conclusions:

  • Barriers to GDMT implementation in Sweden are primarily side effects, limited specialist knowledge, and organizational issues.
  • Educational initiatives and structured nurse-led HF clinics are recommended to improve GDMT adherence.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
318